

7. McGeer A, Campbell B, Emori TG et al. Definitions of infection for surveillance in long-term care facilities. *Am J Infect Control* 1991;19:1–7.
8. Juthani-Mehta M, Tinetti M, Perrelli E et al. Interobserver variability in the assessment of clinical criteria for suspected urinary tract infection in nursing home residents. *Infect Control Hosp Epidemiol* 2008;29:446–449.
9. Went P, Achterberg W, Bruggink R et al. Richtlijn Urineweg-Infecties. [Guideline urinary tract infections]. Utrecht, the Netherlands: Verenoo, Dutch Association of Elderly Care Physicians, 2006.
10. High KP, Bradley SF, Gravenstein S et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. *J Am Geriatr Soc* 2009;57:375–394.
11. Schmiemann G, Knieh E, Gebhardt K et al. The diagnosis of urinary tract infection: A systematic review. *Dtsch Arztebl Int* 2010;107:361–367.
12. van den Hout WB, Caljouw MAA, Putter H et al. Cost-effectiveness of cranberry capsules to prevent urinary tract infections in long-term care facilities: Economic evaluation alongside a randomized controlled trial. *J Am Geriatr Soc* 2014;62:111–116.

REVIEWING THE SAFETY OF LORATADINE FOR ELDERLY ADULTS: A POTENTIAL SHORTCOMING OF THE 2012 BEERS CRITERIA

To the Editor: Anticholinergic drugs produce a variety of adverse effects, including dry mouth and eyes, constipation, blurred vision, rapid heart rate, dizziness, sedation, confusion, delirium, hallucinations, and cognitive impairment.^{1,2} Furthermore, anticholinergic toxicity has been reported as a common problem in elderly adults, and anticholinergic drug use is closely associated with serious negative outcomes in this population, such as risk of falls, behavioral symptoms (including agitation), and high mortality.^{1,2} Anticholinergic drugs are often mentioned in explicit criteria for inappropriate medication use in older adults, such as the Beers criteria.^{1,3} In 2012, the American Geriatrics Society revised these criteria and included loratadine on the list of potentially inappropriate medication for elderly adults owing to its strong anticholinergic properties; these drugs were to be avoided in cases of lower urinary tract symptoms, benign prostatic hyperplasia, chronic constipation, and cognitive impairment and delirium.³

Loratadine is a second-generation H1 antihistamine, as are levocabastine, azelastine, bilastine, desloratadine, ebastine, cetirizine, fexofenadine, levocetirizine, and rupatadine; the characteristics of second-generation H1 antihistamines make them more effective and safer than first-generation H1 antihistamines (e.g., diphenhydramine, hydroxyzine, promethazine, clemastine, triprolidine). Moreover, first-generation H1 antihistamines are associated with undesirable sedation and anticholinergic side effects.^{4–6} Under the umbrella term “sedation” is a range of conditions including somnolence, impaired concentration, and poor learning ability.⁵ Central nervous system (CNS) and cardiac toxicity have been the most serious adverse effects associated with H1 antihistamines. Cardiac toxicity is rare but is of considerable concern because of the associated risk of death. CNS toxicity produced by first-generation H1 antihistamines is widespread, but even during the years when first-generation H1 antihistamines were widely used, case reports of cardiac toxicity were uncommon, and epidemiological studies involving large sample sizes identified only a few cases of H1 antihistamine-associated ventricular arrhythmias.⁷ Thereafter, sev-

eral second-generation H1 antihistamines, the use of which was devoid of any associated cardiac toxicity and significant CNS toxicity,^{5,7} became the H1 antihistamines of choice.⁷

Loratadine is considered a nonsedating antihistamine. At recommended doses (10 mg/d), no significant differences between loratadine and placebo for any measure of cognitive or psychomotor performance, mood, or sedation were observed.^{5,6} In contrast, other performance studies that used higher doses of loratadine (20 and 40 mg) showed significant performance impairment and sedation in some tests (e.g., choice reaction time, adaptive tracking, digit-symbol substitution) in comparison with placebo.⁵ In light of the evidence demonstrating its safety, the inclusion of loratadine in the list of potentially inappropriate medications solely on the basis of the studies that the 2012 revised Beers criteria reference is not justified. Those three studies, which the American Geriatrics Society cited,^{8–10} do not provide any evidence of loratadine being an antihistamine with strong anticholinergic properties. One of these studies⁹ gave loratadine 2 points on the Anticholinergic Risk Scale, indicating that it entails intermediate risk; another study⁸ gave loratadine 0 points, which means that it has no known anticholinergic properties. Moreover, a recent systematic review of anticholinergic risk scales in older adults¹ did not mention that loratadine has strong anticholinergic properties or the potential for serious adverse effects in elderly adults. That review¹ cited two of the three studies that the 2012 Beers criteria referenced;^{8,9} the third study,¹⁰ also used as a reference by the American Geriatrics Society, was not included in the systematic review, probably because it was a narrative review that did not provide any evidence of loratadine possessing strong anticholinergic properties.

That review¹ has great clinical implications because the summarized studies describe different drugs with anticholinergic properties. Although this study was not a systematic review of randomized clinical trials, the data can be applied to clinical practice. The findings of this review provide insights into a broad issue that could have not been addressed through clinical trials. The finding that loratadine is safe for elderly adults is of great consequence to health professionals concerned with providing treatment for people of this age group. In addition, it highlights a probable shortcoming of the Beers criteria, which are currently used as a basis for supporting prescription for elderly adults.³

Márcio Galvão Oliveira, BPharm, PhD
Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Bahia, Brazil

Welma Wildes Amorim, MD
Curso de Medicina, Universidade Estadual do Sudoeste da Bahia, Bahia, Brazil

Alfredo José Rodrigues-Neto
Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Bahia, Brazil

ACKNOWLEDGMENTS

Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and

has determined that the authors have no financial or any other kind of personal conflicts with this paper.

Author Contributions: All authors contributed to review and the preparation of the manuscript.

Sponsor's Role: Not applicable.

REFERENCES

1. Duran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. *Eur J Clin Pharmacol* 2013;69:1485–1496.
2. Tune LE. Anticholinergic effects of medication in elderly patients. *J Clin Psychiatry* 2001;62(Suppl 21):11–14.
3. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. The American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 2012;60:616–631.
4. Braidó F, Scifó F, Ferrando M et al. New therapies for allergic rhinitis. *Curr Allergy Asthma Rep* 2014;14:422.
5. Philpot EE. Safety of second generation antihistamines. *Allergy Asthma Proc* 2000;21:15–20.
6. Kay GG, Harris AG. Loratadine: A non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. *Clin Exp Allergy* 1999;29(Suppl 3):147–150.
7. Juniper EF, Stahl E, Doty RL et al. Clinical outcomes and adverse effect monitoring in allergic rhinitis. *J Allergy Clin Immunol* 2005;115:S390–S413.
8. Carnahan RM, Lund BC, Perry PJ et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. *J Clin Pharmacol* 2006;46:1481–1486.
9. Rudolph JL, Salow MJ, Angelini MC et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. *Arch Intern Med* 2008;168:508–513.
10. Boustani M, Campbell N, Munger S et al. Impact of anticholinergics on the aging brain: A review and practical application. *Aging Health* 2008;4:311–320.

RESPONSE TO MÁRCIO GALVÃO OLIVEIRA ET AL.

To the Editor: Thank you for your letter regarding your concerns about the presence of loratadine on the American Geriatrics Society Beers criteria and the performance and safety data for loratadine and other anticholinergic drugs.¹ The current support of the American Geriatrics

Society for regular updates of the criteria and our improved methodology for the Beers criteria allow for more-frequent review and grading of the available studies and data. We are currently in the process of revising the criteria, with an expected update in late 2015. We also noted that several of the studies that the review in the letter by Oliveira and colleagues cited included healthy individuals aged 18 to 51. This is an important consideration when reviewing evidence for the Beers criteria. We will review and grade the evidence for the studies you suggested, along with the other available and emerging evidence on this medication.

Co-chairs of the AGS 2012 Beers Criteria Update.

Todd Semla, MS, PharmD

*Department of Veterans Affairs, Pharmacy Benefits Management Services, Hines, Illinois
Departments of Medicine, Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois*

Donna M. Fick, RN, PhD

Hartford Center for Geriatric Nursing Excellence, College of Nursing, The Pennsylvania State University, State College, Pennsylvania

ACKNOWLEDGMENTS

Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper.

Author Contributions: Both authors contributed to this paper.

Sponsor's Role: None.

REFERENCE

1. Oliveira MG, Amorim WW, Rodrigues-Neto AJ. Reviewing the safety of loratadine for elderly adults: A potential shortcoming of the 2012 Beers criteria. *J Am Geriatr Soc* 2014;62:1618–1619.